Company Filing History:
2 out of 2,496 
2 out of 1,165 
2 out of 1,874 
Years Active: 2011-2015
Title: Jennifer Machen: Innovator in Autoimmune Diabetes Treatment
Introduction
Jennifer Machen is a notable inventor based in Export, Pennsylvania, who has made significant contributions to the field of autoimmune diabetes treatment. With a total of two patents to her name, her work focuses on innovative approaches to induce dendritic cell tolerance, particularly in the context of type 1 diabetes.
Latest Patents
Machen's latest patents revolve around the delivery of AS-oligonucleotide microspheres designed to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes. These AS-oligonucleotides are delivered in microsphere form, specifically targeting the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense oligonucleotides, and the process involves using an antisense approach to prevent autoimmune diabetes conditions in NOD mice both in vivo and in situ. The oligonucleotides are strategically targeted to bind to primary transcripts CD40, CD80, CD86, and their combinations.
Career Highlights
Throughout her career, Jennifer Machen has worked with prominent companies such as Baxter International Inc. and Baxter Healthcare SA. Her experience in these organizations has contributed to her expertise in the field of biomedical innovations.
Collaborations
Machen has collaborated with notable individuals in her field, including Larry Richard Brown and Vered Bisker-Leib. These collaborations have likely enriched her research and development efforts.
Conclusion
Jennifer Machen stands out as an innovative inventor dedicated to advancing treatments for autoimmune diabetes. Her contributions through her patents and collaborations reflect her commitment to improving health outcomes in this critical area.